MALVERN, Pa., July 20, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced that it has been awarded a group purchasing agreement for Synthetic Bioabsorbable Mesh Products with Premier, Inc. Effective October 1st, 2022, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for OviTex® and OviTex PRS Reinforced Tissue Matrix.
Premier (NASDAQ: PINC) is a leading healthcare improvement company, uniting an alliance of approximately 4,400 U.S. hospitals and 225,000 other providers and organizations to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost.
“We are both grateful and honored to be awarded this important agreement,” said Antony Koblish, President and CEO of TELA Bio. “This is a significant opportunity for our company, and we look forward to working with Premier members to provide their surgeons and patients with access to our advanced soft-tissue repair portfolio.”
OviTex and OviTex PRS Reinforced Tissue Matrix are a next generation soft tissue repair platform for use in general, plastic and reconstructive surgery. OviTex utilizes layers of naturally sourced tissue interwoven with permanent or resorbable polymer suture to facilitate tissue remodeling, optimize strength, and minimize permanent synthetic foreign body footprint. To learn more, please visit www.telabio.com/ovitex.html.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
CONTACT:
TELA Bio Contact
Greg Firestone
Vice President, Strategic Customer Relations
224-612-0792
gfirestone@telabio.com
Media Contact
Alyson Kuritz
908-892-7149
alyson@0to5.com
Investor Contact
Greg Chodaczek
332-895-3230
ir@telabio.com
